Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $86.80 Average Price Target from Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $86.80.

A number of research firms have recently weighed in on GPCR. Morgan Stanley assumed coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. JMP Securities dropped their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $1,064,000. Bellevue Group AG boosted its holdings in shares of Structure Therapeutics by 2,858.7% during the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock valued at $15,598,000 after buying an additional 351,626 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Structure Therapeutics in the 2nd quarter worth about $1,178,000. First Light Asset Management LLC grew its position in shares of Structure Therapeutics by 296.1% in the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock worth $23,195,000 after buying an additional 441,534 shares during the period. Finally, Blue Owl Capital Holdings LP purchased a new position in Structure Therapeutics during the 2nd quarter valued at about $2,160,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $41.14 on Friday. Structure Therapeutics has a 1-year low of $26.61 and a 1-year high of $74.21. The business has a 50 day moving average of $39.57 and a 200 day moving average of $39.76. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -54.85 and a beta of -3.53.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, sell-side analysts anticipate that Structure Therapeutics will post -0.79 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.